James Kochenderfer, MD, on Inducing Remissions in B-Cell Lymphoma
2016 ASCO Annual MeetingJames Kochenderfer, MD, of the National Cancer Institute, discuss results of a small study on genetically modified CAR-T cells, which may well become a standard lymphoma treatment (Abstract LBA3010).
Related Videos
Sagar Lonial, MD, and Andrew Zelenetz, MD, PhD, on MCL, DLBCL, CLL: How Much Rituximab Is Enough?
Sagar Lonial, MD, of Emory University School of Medicine, and Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discuss newly reported findings ...
Helen MacKay, MD, on Epithelial Ovarian Cancer: Results From the OV21/PETROC Trial
Helen MacKay, MD, of the Sunnybrook Odette Cancer Centre, discusses findings from this phase II study of intraperitoneal vs intravenous chemotherapy following neoadjuvant...
Sumanta K. Pal, MD, and Toni K. Choueiri, MD, on Urothelial Carcinoma: Efficacy of an FGFR Inhibitor
Sumanta K. Pal, MD, of City of Hope, and Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discuss findings on BGJ398 in patients with previously treated advance...
Salah-Eddin Al-Batran, MD, on Gastric and GEJ Adenocarcinoma: Results From the FAST Trial
Salah-Eddin Al-Batran, MD, of the Institute of Clinical Cancer Research and Nordwest Hospital, discusses findings from this international phase II study of epirubicin, oxaliplatin, an...
Nikhil Wagle, MD, on The Metastatic Breast Cancer Project: Progress Report
Nikhil Wagle, MD, of the Dana-Farber Cancer Institute, discusses the strides made in this national direct-to-patient initiative to accelerate genomics research (Abstract LBA1519).
